Access to medicines and pharmaceutical patents: civil society struggle for the right to health, facing the transnational pharmaceutical corporations

Detalhes bibliográficos
Autor(a) principal: Villardi, Pedro
Data de Publicação: 2017
Outros Autores: Fonseca, Felipe
Tipo de documento: Artigo
Idioma: por
Título da fonte: Homa Publica (Online)
Texto Completo: https://periodicos.ufjf.br/index.php/HOMA/article/view/30544
Resumo: Access to medicines and pharmaceutical patents have been the subject of debate, especially since the creation of the WTO and the TRIPS Agreement in the early 1990s. In a strategic alliance, developed countries and corporations have articulated the obligation to have patents for medicines. They argued that there would be no further medical innovations without monopoly incentive, to recover investments. However, two decades later, there is plenty of data proving how fallacious this argument was/is. In this article, we will present the impacts of pharmaceutical patents on access to medicines and medical innovation and we will argue that only with a systemic confrontation with corporate power it is possible guarantee access to medicines and pharmaceutical innovation based on health needs.
id UFJF-5_ae627d9ceed5ecd01927fcb41eaa4ed7
oai_identifier_str oai:periodicos.ufjf.br:article/30544
network_acronym_str UFJF-5
network_name_str Homa Publica (Online)
repository_id_str
spelling Access to medicines and pharmaceutical patents: civil society struggle for the right to health, facing the transnational pharmaceutical corporationsAcesso a medicamentos e patentes farmacêuticas: a luta da sociedade civil pelo direito à saúde frente às corporações farmacêuticas transnacionais Acesso a medicamentosPatentes farmacêuticasCorporações transnacionaisDireito à saúdeAccess to medicinesPharmaceutical patentsTransnational corporationsRight to healthAccess to medicines and pharmaceutical patents have been the subject of debate, especially since the creation of the WTO and the TRIPS Agreement in the early 1990s. In a strategic alliance, developed countries and corporations have articulated the obligation to have patents for medicines. They argued that there would be no further medical innovations without monopoly incentive, to recover investments. However, two decades later, there is plenty of data proving how fallacious this argument was/is. In this article, we will present the impacts of pharmaceutical patents on access to medicines and medical innovation and we will argue that only with a systemic confrontation with corporate power it is possible guarantee access to medicines and pharmaceutical innovation based on health needs.Acesso a medicamentos e patentes farmacêuticas têm sido alvo de intensos debates, principalmente a partir da criação da OMC e da assinatura do Acordo TRIPS, no início dos anos 1990. Em uma aliança estratégica, países desenvolvidos e corporações farmacêuticas, articularam a obrigatoriedade do patenteamento de medicamentos, argumentando que não haveria mais inovações sem o incentivo do monopólio, para recuperação do investimento. No entanto, duas décadas depois, não faltam dados para comprovar quão falacioso era esse argumento. Neste artigo apresentaremos os impactos das patentes farmacêuticas no acesso a medicamentos e na inovação médica e defenderemos que somente a partir do enfrentamento sistêmico do poder das corporações é possível garantir acesso a medicamentos e inovação farmacêutica, baseada em necessidade de saúde.  Universidade Federal de Juiz de Fora2017-07-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer ReviewedRevisado por paresAvaliado pelos paresapplication/pdfhttps://periodicos.ufjf.br/index.php/HOMA/article/view/30544Homa Publica - Revista Internacional de Derechos Humanos y Empresas; Vol. 1 No. 2 (2017); e:018Homa Publica - Revista Internacional de Derechos Humanos y Empresas; Vol. 1 Núm. 2 (2017); e:018Homa Publica - Revista Internacional de Derechos Humanos y Empresas; v. 1 n. 2 (2017); e:0182526-0774reponame:Homa Publica (Online)instname:Universidade Federal de Juiz de Fora (UFJF)instacron:UFJFporhttps://periodicos.ufjf.br/index.php/HOMA/article/view/30544/20546Derechos de autor 2017 Homainfo:eu-repo/semantics/openAccessVillardi, PedroFonseca, Felipe2021-12-29T18:44:47Zoai:periodicos.ufjf.br:article/30544Revistahttps://periodicos.ufjf.br/index.php/HOMAPUBhttps://periodicos.ufjf.br/index.php/HOMA/oairevista.homa@ufjf.edu.br||2526-07742526-0774opendoar:2021-12-29T18:44:47Homa Publica (Online) - Universidade Federal de Juiz de Fora (UFJF)false
dc.title.none.fl_str_mv Access to medicines and pharmaceutical patents: civil society struggle for the right to health, facing the transnational pharmaceutical corporations
Acesso a medicamentos e patentes farmacêuticas: a luta da sociedade civil pelo direito à saúde frente às corporações farmacêuticas transnacionais
title Access to medicines and pharmaceutical patents: civil society struggle for the right to health, facing the transnational pharmaceutical corporations
spellingShingle Access to medicines and pharmaceutical patents: civil society struggle for the right to health, facing the transnational pharmaceutical corporations
Villardi, Pedro
Acesso a medicamentos
Patentes farmacêuticas
Corporações transnacionais
Direito à saúde
Access to medicines
Pharmaceutical patents
Transnational corporations
Right to health
title_short Access to medicines and pharmaceutical patents: civil society struggle for the right to health, facing the transnational pharmaceutical corporations
title_full Access to medicines and pharmaceutical patents: civil society struggle for the right to health, facing the transnational pharmaceutical corporations
title_fullStr Access to medicines and pharmaceutical patents: civil society struggle for the right to health, facing the transnational pharmaceutical corporations
title_full_unstemmed Access to medicines and pharmaceutical patents: civil society struggle for the right to health, facing the transnational pharmaceutical corporations
title_sort Access to medicines and pharmaceutical patents: civil society struggle for the right to health, facing the transnational pharmaceutical corporations
author Villardi, Pedro
author_facet Villardi, Pedro
Fonseca, Felipe
author_role author
author2 Fonseca, Felipe
author2_role author
dc.contributor.author.fl_str_mv Villardi, Pedro
Fonseca, Felipe
dc.subject.por.fl_str_mv Acesso a medicamentos
Patentes farmacêuticas
Corporações transnacionais
Direito à saúde
Access to medicines
Pharmaceutical patents
Transnational corporations
Right to health
topic Acesso a medicamentos
Patentes farmacêuticas
Corporações transnacionais
Direito à saúde
Access to medicines
Pharmaceutical patents
Transnational corporations
Right to health
description Access to medicines and pharmaceutical patents have been the subject of debate, especially since the creation of the WTO and the TRIPS Agreement in the early 1990s. In a strategic alliance, developed countries and corporations have articulated the obligation to have patents for medicines. They argued that there would be no further medical innovations without monopoly incentive, to recover investments. However, two decades later, there is plenty of data proving how fallacious this argument was/is. In this article, we will present the impacts of pharmaceutical patents on access to medicines and medical innovation and we will argue that only with a systemic confrontation with corporate power it is possible guarantee access to medicines and pharmaceutical innovation based on health needs.
publishDate 2017
dc.date.none.fl_str_mv 2017-07-31
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer Reviewed
Revisado por pares
Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://periodicos.ufjf.br/index.php/HOMA/article/view/30544
url https://periodicos.ufjf.br/index.php/HOMA/article/view/30544
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://periodicos.ufjf.br/index.php/HOMA/article/view/30544/20546
dc.rights.driver.fl_str_mv Derechos de autor 2017 Homa
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2017 Homa
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Juiz de Fora
publisher.none.fl_str_mv Universidade Federal de Juiz de Fora
dc.source.none.fl_str_mv Homa Publica - Revista Internacional de Derechos Humanos y Empresas; Vol. 1 No. 2 (2017); e:018
Homa Publica - Revista Internacional de Derechos Humanos y Empresas; Vol. 1 Núm. 2 (2017); e:018
Homa Publica - Revista Internacional de Derechos Humanos y Empresas; v. 1 n. 2 (2017); e:018
2526-0774
reponame:Homa Publica (Online)
instname:Universidade Federal de Juiz de Fora (UFJF)
instacron:UFJF
instname_str Universidade Federal de Juiz de Fora (UFJF)
instacron_str UFJF
institution UFJF
reponame_str Homa Publica (Online)
collection Homa Publica (Online)
repository.name.fl_str_mv Homa Publica (Online) - Universidade Federal de Juiz de Fora (UFJF)
repository.mail.fl_str_mv revista.homa@ufjf.edu.br||
_version_ 1797077453773996032

Registros relacionados